Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …

Vaccination affords protection from disease by activating pathogen-specific immune cells
and facilitating the development of persistent immunologic memory toward the vaccine …

Adoptive T cell transfer therapy (ACT) using tumor infiltrating lymphocytes or lymphocytes
redirected with antigen receptors (CAR or TCR) has revolutionized the field of cancer …

T cell-based adoptive cell therapy (ACT) has exhibited excellent antitumoral efficacy
exemplified by the clinical breakthrough of chimeric antigen receptor therapy (CAR-T) in …

CAR T cell qualities, such as persistence and functionality play important roles in
determining the outcome of cancer immunotherapy. In spite of full functionality, it has been …

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic
landscape of haematological malignancies. However, resistance and relapse remain …

Purpose: Although CD19 chimeric antigen receptor T cells (CAR-T) therapy has shown
remarkable success in B-cell malignancies, a substantial fraction of patients do not obtain a …

Abstract CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of
B cell malignancies. However, relapse of primary disease remains a major obstacle after …

Although tumor-infiltrating T lymphocytes (TIL-Ts) play a crucial role in solid tumor
immunotherapy, their clinical application has been limited because of the …

Introduction: In recent years, immunotherapy for the treatment of solid cancer has emerged
as a promising therapeutic alternative. Adoptive cell therapy (ACT), especially T cell-based …